Completed PHASE2 INTERVENTIONAL 2-arm NCT01237119

Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis (LEAN)

48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes

Sponsor: Novo Nordisk A/S

Conditions Nonalcoholic Steatohepatitis

Interventions Liraglutide Liraglutide-placebo

Updated 5 times since 2017 Last updated: Mar 22, 2016 Started: Aug 31, 2010 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Nonalcoholic Steatohepatitis and is currently completed. Novo Nordisk A/S leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S
University of Birmingham
Wellcome Trust

Data source: University of Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United Kingdom